Clinical Trials

250 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05624554 2026-03-16

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

300 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06091254 2026-03-11

OLYMPIA-1

822 enrolled

Lymphoma, Follicular

NCT05139017 2026-03-10

waveLINE-003

Phase 2/3 Recruiting

290 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03336333 2026-03-09

SEQUOIA

590 enrolled 12 charts 1 FDA

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04663347 2026-03-03

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT06084936 2026-03-03

GLOBRYTE

182 enrolled

Lymphoma

NCT06191744 2026-03-03

EPCORE™FL-2

1,095 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT02972840 2026-02-18

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

635 enrolled 1 FDA

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT06522737 2026-02-11

TERZO

124 enrolled

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral

NCT04674813 2026-02-09

A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 1 Completed

130 enrolled

Plasma cell

Multiple Myeloma

NCT02970318 2026-02-06

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

310 enrolled 18 charts 1 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05023980 2026-01-22

BRUIN CLL-313

309 enrolled

Phase 2 Active not recruiting

Hematologic Diseases, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT06425302 2026-01-08

GOLSEEK-2

90 enrolled

Lymphoma, Lymphoma, Follicular

NCT06970743 2026-01-07

CaDAnCe-303

150 enrolled